1. Context: India–EU FTA and Strategic Trade Rebalancing
The proposed India–European Union Free Trade Agreement (FTA) marks a significant shift in India’s engagement with advanced markets, particularly in high-value, regulation-intensive sectors such as pharmaceuticals, chemicals, and medical devices. The EU’s offer to eliminate tariffs on 97.5% of Indian chemical exports signals deeper economic integration.
For India, the agreement goes beyond tariff liberalisation; it creates preferential market access in one of the world’s most stringently regulated yet lucrative markets. This is especially relevant as global trade fragments and countries seek trusted partners for critical supply chains.
If leveraged effectively, the FTA can strengthen India’s position in global health and life-sciences value chains. If ignored or poorly implemented, however, India risks remaining confined to low-margin segments despite tariff advantages.
The broader governance logic is that trade agreements today are instruments of strategic positioning, not merely tariff reduction.
2. Tariff Liberalisation in Pharmaceuticals and Chemicals
Under the proposed framework, the EU will reduce tariffs of up to 12.8% on Indian chemical exports to zero. Similarly, Indian tariffs on EU chemical exports will fall from 22% to zero, indicating reciprocal market opening.
Although Indian pharmaceutical exports already enter the EU largely duty-free, the agreement enhances preferential access and competitiveness, particularly against non-FTA countries. The removal of EU tariffs of up to 11% is expected to support greater trade volumes and innovation flows.
“The expected removal of EU tariffs of up to 11 per cent on pharma will enhance trade and support greater access to innovative medicines for Indian patients.” — Sudarshan Jain, Indian Pharmaceutical Alliance
Preferential access matters even where tariffs are low, as it improves relative competitiveness and investment certainty.
3. Export Profile and Market Opportunity for Indian Pharma
India’s pharmaceutical exports to Europe were valued at approximately $5.8 billion in 2024–25, accounting for 19–21% of India’s total pharma exports. This highlights the EU’s importance as a destination market.
Export composition:
- 75–80%: Generic formulations and biosimilars
- Remainder: APIs, bulk drugs, and vaccines
The agreement opens opportunities for Indian firms to compete in the EU’s $2 billion market for biosimilars and complex generics, segments characterised by high entry barriers and strong margins.
Access to regulated markets like the EU acts as a quality signal, reinforcing India’s credibility in global pharmaceutical supply chains.
4. Implications for Pharma MSMEs and Cost Competitiveness
The FTA is particularly consequential for India’s pharmaceutical micro, small, and medium enterprises (MSMEs). Many possess strong manufacturing and quality capabilities but face cost and compliance barriers in entering the EU.
Reduced tariffs, regulatory cooperation, and improved Customs facilitation can lower transaction costs and shorten approval timelines, enabling smaller exporters to scale up.
“Trade agreements can help firms move up the value chain, provided regulatory barriers are addressed alongside tariffs.” — World Trade Organization, World Trade Report
Without complementary regulatory facilitation, tariff liberalisation alone may disproportionately benefit larger firms.
5. Impact on Prices, Innovation, and Patient Access
Experts expect the FTA to lower the cost of advanced therapies and medical products in India through technology collaboration and scale effects.
Price impact projections:
- 10–20% reduction in the short term
- 40–70% reduction over 2–3 years as local manufacturing, biosimilars, and patent expiries align
This has implications for affordability, public health outcomes, and domestic innovation ecosystems.
Trade liberalisation, when combined with local manufacturing, can translate external openness into domestic welfare gains.
6. Medical Devices and MedTech Sector Gains
The agreement eliminates tariffs of up to 27.5% on 90% of medical and surgical equipment, and up to 6.7% across 99.1% of trade lines for medical instruments and appliances.
India’s medtech exports to the EU currently focus on consumables and low-to-mid risk devices such as catheters, gloves, dressings, and diagnostics. Zero-duty access improves cost competitiveness in a highly regulated market.
“Regulatory convergence and tariff rationalisation are essential for making medical devices affordable and globally competitive.” — World Health Organization, Medical Devices Technical Series
Tariff elimination must be complemented by regulatory alignment to unlock full export potential.
7. Regulatory Challenges and Safeguards
Despite tariff benefits, Indian medtech firms operate in an expensive and complex EU regulatory environment. Compliance costs, certification timelines, and documentation requirements remain significant hurdles.
Industry representatives stress the need for fair regulatory alignment and safeguards against predatory imports, particularly from third countries routing goods through the EU.
If regulatory asymmetries persist, tariff liberalisation may not translate into meaningful market access for Indian manufacturers.
8. Services Dimension: AYUSH and Traditional Medicine
Beyond goods, the FTA extends to services, notably India’s traditional medicine systems. AYUSH practitioners will be allowed to provide services in EU member states where no specific regulations exist, based on Indian professional qualifications.
The agreement also locks in future openness for establishing AYUSH wellness centres and clinics in the EU, providing long-term certainty for service exports.
“Trade in services is increasingly central to modern trade agreements.” — OECD, Services Trade Policy
Services liberalisation diversifies India’s export basket and strengthens cultural and economic linkages.
9. Market Signalling and Investor Confidence
The positive reaction of equity markets, with the Nifty Pharma index rising 0.3%, reflects investor optimism regarding export growth and profitability. Gains in firms such as JB Pharma, Torrent, Glenmark, and Zydus underscore expectations of medium-term benefits.
Market responses act as forward-looking indicators of confidence in policy stability and global integration.
Investor sentiment reinforces the credibility of trade policy as a growth enabler.
Conclusion
The India–EU FTA represents a strategic opportunity to integrate India more deeply into high-value pharmaceutical and medical technology markets. By combining tariff liberalisation with regulatory cooperation, technology collaboration, and services access, the agreement can enhance competitiveness, affordability, and innovation. Its long-term success, however, will depend on effective implementation, regulatory alignment, and safeguards that ensure inclusive gains across firm sizes and sectors.
.jpeg){kind=small}
.jpeg){kind=small}